Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Chadi
C
Nabhan
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000191:economics / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D000077143:Docetaxel; D006801:Humans; D007167:Immunotherapy / Q000191:economics*; D008297:Male; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*; D043823:Taxoids / Q000191:economics / Q000627:therapeutic use; D014020:Tissue Extracts / Q000191:economics / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D043823:Taxoids; D014020:Tissue Extracts; D000077143:Docetaxel; C511774:sipuleucel-T